Maxygen Gains $3.4M from DOD for Protein Reshuffling Technology | GenomeWeb
NEW YORK (GenomeWeb News) – Maxygen has received a $3.4 million grant from the US Department of Defense to develop its genetic reshuffling technology through a collaboration with the DNA-based vaccine services provider Aldevron, the company said today.
The firm’s ParallelaVax system is used for rapid, high-throughput screening of vaccine candidates in animals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.